Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed breast cancer * Metastatic disease * Measurable disease, defined as \>=1 unidimensionally measurable lesion, including \>= 1 of the following: * Lesion \>= 10 mm on CT scan (5 mm sections) * Lesion \>= 20 mm on CT scan or MRI (10 mm sections) * Bone disease that is \>= 10 mm on MRI * Lytic bone lesions that are \>= 10 mm on CT scan (with 5 mm sections) OR \>= 20 mm on plain film or CT scan (with 10 mm sections) * Lesion \>= 10 mm on physical exam * Patients must have received \>= 1 prior aromatase inhibitor in either the adjuvant or metastatic setting and must have had either disease recurrence or disease progression on a prior aromatase inhibitor therapy * No brain metastases diagnosed within the past 6 months OR previously untreated brain metastases * Estrogen receptor-positive and/or progesterone receptor-positive, defined as \> 1% staining by immunohistochemistry or \> 10 fmol/mg of protein by radio-ligand dextran-coated steroid binding assay * Postmenopausal, as defined by 1 of the following: * Prior bilateral oophorectomy * No menses for \>= 12 months in patients with an intact uterus * Follicle-stimulating hormone (FSH) in postmenopausal range in patients \< 60 years of age who have had a prior hysterectomy or have been amenorrheic for \>= 3 months * Age \>= 60 years * Pre- or perimenopausal patients receiving monthly injections of goserelin at a dose of 3.6 mg are eligible * ECOG 0-2 * More than 3 months * Absolute neutrophil count \>= 1,500/mm3 Platelet count \>= 100,000/mm3 No bleeding diathesis * Bilirubin =\< 1.5 times upper limit of normal (ULN AST and ALT =\< 2.5 times ULN * Systolic blood pressure (BP) \< 150 mm Hg and diastolic BP \< 100 mm Hg on at least one reading prior to study entry No uncontrolled hypertension * None of the following within the past 6 months: * Symptomatic congestive heart failure * Unstable angina pectoris * Myocardial infarction * Cardiac arrhythmia with hemodynamic compromise * Not pregnant or nursing * Able to swallow oral medication * No known HIV positivity * No ongoing or active infection * No psychiatric illness or social situation that would preclude study compliance * No other active invasive malignancy within the past 5 years except nonmelanoma skin cancer or treated carcinoma in situ of the cervix * No other uncontrolled illness * More than 4 weeks since prior chemotherapy * No more than 2 prior chemotherapy regimens for metastatic disease * At least 8 weeks since prior anastrozole therapy * Concurrent steroids allowed if dose is stable * More than 4 weeks since prior radiotherapy * More than 4 weeks since prior major surgery * Recovered from prior therapy * No prior sorafenib * No concurrent therapeutic anticoagulation * Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided PT and PTT are =\< 1.5 times ULN * No concurrent agents that may interact with sorafenib, including any of the following: * Hypericum perforatum (St. John's wort) * Rifampin * P450 CYP3A4 enzyme-inducing anticonvulsants (e.g., phenytoin, carbamazepine, or phenobarbital) * No other concurrent investigational agents Exclusion Criteria: * estrogen receptor status unknown * history of myocardial infarction within 6 months * performance status 3 * performance status 4 * premenopausal * progesterone receptor status unknown * HIV positive